Intermountain Healthcare Utah, The University of Texas Health Science Center at Houston (UTHealth), and Rush University Medical Center have joined physIQ’s DeCODe project to develop a Covid-19 digital biomarker based on artificial intelligence (AI) in the United States.
These institutions will serve as recruiting sites and critical collaborators in Phase II validation for the DeCODe project financed by the US National Institutes of Health (NIH). The creation of biomarkers could enable the early detection of a rapid clinical decompensation in Covid-19 individuals at higher risk. Intermountain Healthcare comprises 25 hospitals, 225 clinics, and a medical group of 2,600 doctors and advanced practice clinicians.
According to the company, the DeCODe study, along with other physIQ-led research, will aid in recognizing the early signs of an inflammatory reaction in particular individuals, according to the company. The National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering announced in January that they would enter Phase II of a multi-phase contract with physIQ to enhance the development of AI-based digital biomarkers for Covid-19.
Following the positive findings of DeCODe’s Phase I, physIQ applied for a piece of the $1.5 million federal government program to evaluate Covid-19 patients with long-term symptoms, also known as long haulers. For this long haulers study, physIQ is collaborating with Intermountain, UTHealth, and Rush.